Biogen’s Statement on the Draft National Coverage Determination (NCD) for Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer’s Disease
Alzheimer’s patients and their families deserve to have choice and access to FDA-approved treatments. Biogen believes that the proposed coverage with evidence development (CED) decision for anti-amyloid therapies denies nearly all Medicare beneficiaries from accessing ADUHELM® (aducanumab-avwa) 100
Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will host an analyst Q&A call on Thursday, January 13, 2022, at 8:00 a.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at investors.biogen.com .
Cambridge, MA, - - Biogen Inc. (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at
Sustainability Report: 2020 Year in Review
Learn more about what actions we are taking to deliver on our bold and unwavering commitments to our patients, employees, environment and communities.